Literature DB >> 11124065

Gene transfer into the fetal primate: evidence for the secretion of transgene product.

J E Larson1, S L Morrow, J B Delcarpio, R P Bohm, M S Ratterree, J L Blanchard, J C Cohen.   

Abstract

In utero adenoviral-mediated transfer of genes via the amniotic fluid results in sustained high-efficiency expression in rodent lung and intestine. Rhesus macaque (Macaca mulatta) fetuses were injected with adenovirus vectors encoding reporter genes at different gestational ages to evaluate feasibility and timing in primates. The fetuses developed normally following gene transfer and no maternal adverse affects were noted. Highly efficient viral uptake and transgene protein expression occurred in the target organs. The lungs exhibited no immune response and transgenic protein was observed up to 30 days postinfection. Unexpectedly, large amounts of reporter gene protein were released, apparently from the lung, into the circulation and accumulated in the renal proximal tubules and bladder. PCR detection for adenovirus DNA was consistently negative in tissues not in contact with the amniotic fluid, such as kidneys, liver, gonads, and eyes. Treatment of primate fetuses at 110 days gestation with an adenovirus expressing the cystic fibrosis transmembrane conductance regulator (cftr) gene resulted in accelerated differentiation of the lung. These studies demonstrate the efficacy of in utero gene therapy in primates and its potential application to genetic diseases.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11124065     DOI: 10.1006/mthe.2000.0209

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   11.454


  13 in total

1.  Intra-amniotic rAAV-mediated microdystrophin gene transfer improves canine X-linked muscular dystrophy and may induce immune tolerance.

Authors:  Hiromi Hayashita-Kinoh; Naoko Yugeta; Hironori Okada; Yuko Nitahara-Kasahara; Tomoko Chiyo; Takashi Okada; Shin'ichi Takeda
Journal:  Mol Ther       Date:  2015-01-14       Impact factor: 11.454

2.  Small interfering peptide (siP) for in vivo examination of the developing lung interactonome.

Authors:  J Craig Cohen; Erin Killeen; Avinash Chander; Ken-Ichi Takemaru; Janet E Larson; Kate J Treharne; Anil Mehta
Journal:  Dev Dyn       Date:  2009-02       Impact factor: 3.780

3.  Transient in utero knockout (TIUKO) of C-MYC affects late lung and intestinal development in the mouse.

Authors:  J Craig Cohen; Donald K Scott; James Miller; Jianxuan Zhang; Pengbo Zhou; Janet E Larson
Journal:  BMC Dev Biol       Date:  2004-04-16       Impact factor: 1.978

4.  Pathophysiologic consequences following inhibition of a CFTR-dependent developmental cascade in the lung.

Authors:  J Craig Cohen; Janet E Larson
Journal:  BMC Dev Biol       Date:  2005-02-04       Impact factor: 1.978

Review 5.  Barriers to and new approaches for gene therapy and gene delivery in cystic fibrosis.

Authors:  Stefano Ferrari; Duncan M Geddes; Eric W F W Alton
Journal:  Adv Drug Deliv Rev       Date:  2002-12-05       Impact factor: 15.470

6.  Adult onset lung disease following transient disruption of fetal stretch-induced differentiation.

Authors:  Joseph J Hudak; Erin Killeen; Ashok Chandran; J Craig Cohen; Janet E Larson
Journal:  Respir Res       Date:  2009-05-06

7.  The Peter Pan paradigm.

Authors:  J Craig Cohen; Janet E Larson
Journal:  Theor Biol Med Model       Date:  2008-01-08       Impact factor: 2.432

8.  In utero recombinant adeno-associated virus gene transfer in mice, rats, and primates.

Authors:  Deiadra J Garrett; Janet E Larson; Daisy Dunn; Luis Marrero; J Craig Cohen
Journal:  BMC Biotechnol       Date:  2003-09-30       Impact factor: 2.563

9.  Long term physiologic modification using rAAV in utero gene-therapy.

Authors:  Deiadra J Garrett; J Craig Cohen; Janet E Larson
Journal:  Genet Vaccines Ther       Date:  2004-05-19

10.  CFTR and Wnt/beta-catenin signaling in lung development.

Authors:  J Craig Cohen; Janet E Larson; Erin Killeen; Damon Love; Ken-Ichi Takemaru
Journal:  BMC Dev Biol       Date:  2008-07-06       Impact factor: 1.978

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.